Source:http://linkedlifedata.com/resource/pubmed/id/20410922
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-6-10
|
| pubmed:abstractText |
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1476-5551
|
| pubmed:author |
pubmed-author:AndersonK CKC,
pubmed-author:Avet-LoiseauHH,
pubmed-author:BarlogieBB,
pubmed-author:BladeJJ,
pubmed-author:BoccadoroMM,
pubmed-author:ChenW MWM,
pubmed-author:DimopoulosMM,
pubmed-author:DurieB G MBG,
pubmed-author:EinseleHH,
pubmed-author:GreippPP,
pubmed-author:HajduGG,
pubmed-author:International Myeloma Working Group,
pubmed-author:KrögerNN,
pubmed-author:KyleR ARA,
pubmed-author:LandgrenOO,
pubmed-author:LudwigHH,
pubmed-author:MerliniGG,
pubmed-author:PalumboAA,
pubmed-author:PavlovskySS,
pubmed-author:RajkumarS VSV,
pubmed-author:RichardsonP GPG,
pubmed-author:San MiguelJJ,
pubmed-author:SonneveldPP,
pubmed-author:TuressonII,
pubmed-author:VescioRR,
pubmed-author:VesoleD HDH,
pubmed-author:WestinJJ
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1121-7
|
| pubmed:meshHeading |
pubmed-meshheading:20410922-Disease Progression,
pubmed-meshheading:20410922-Humans,
pubmed-meshheading:20410922-Monoclonal Gammopathy of Undetermined Significance,
pubmed-meshheading:20410922-Multiple Myeloma,
pubmed-meshheading:20410922-Practice Guidelines as Topic,
pubmed-meshheading:20410922-Prognosis,
pubmed-meshheading:20410922-Risk Factors
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
|
| pubmed:affiliation |
Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. kyle.robert@mayo.edu
|
| pubmed:publicationType |
Journal Article,
Review
|